Researchers say they have identified an unintended effect of Medicare’s 340B Drug Pricing Program; increases in spending for outpatient cancer treatments among patients with commercial insurance.
Your search for bevacizumab returned 8 results
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
There was no improvement in overall survival with bevacizumab.
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
Study shows reductions in intraocular pressures and antiglaucoma medication use.